Literature DB >> 31733173

Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial.

David Eldred-Evans1,2, Joana B Neves3,4, Lucy A M Simmons3,4, Abi Kanthabalan3,4, Neil McCartan3, Taimur T Shah1,2,3, Manit Arya1,2,3, Susan C Charman5,6, Alex Freeman7, Caroline M Moore3,4, Shonit Punwani8,9, Mark Emberton3,4, Hashim U Ahmed1,2,3.   

Abstract

OBJECTIVE: To determine the additional diagnostic value of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCE) in men requiring a repeat biopsy within the PICTURE study. PATIENTS AND METHODS: PICTURE was a paired-cohort confirmatory study in which 249 men who required further risk stratification after a previous non-magnetic resonance imaging (MRI)-guided transrectal ultrasonography-guided biopsy underwent a 3-Tesla (3T) multiparametic (mp)MRI consisting of T2-weighted imaging (T2W), DWI and DCE, followed by transperineal template prostate mapping biopsy. Each mpMRI was reported using a LIKERT score in a sequential blinded manner to generate scores for T2W, T2W+DWI and T2W+DWI+DCE. Area under the receiver-operating characteristic curve (AUROC) analysis was performed to compare the diagnostic accuracy of each combination. The threshold for a positive mpMRI was set at a LIKERT score ≥3. Clinically significant prostate cancer was analysed across a range of definitions including UCL/Ahmed definition 1 (primary definition), UCL/Ahmed definition 2, any Gleason ≥3 + 4 and any Gleason ≥4 + 3.
RESULTS: Of 249 men, sequential MRI reporting was available for 246. There was a higher rate of equivocal lesions (44.6%) using T2W alone compared to the addition of DWI (23.9%) and DCE (19.8%). Using the primary definition of clinically significant disease, there was no significant difference in the overall accuracy between T2W, with an AUROC of 0.74 (95% confidence interval [CI] 0.68-0.80), T2W+DWI at 0.76 (95% CI 0.71-0.82), and T2W+DWI+DCE, with an AUROC of 0.77 (95% CI 0.71-0.82; P = 0.55). The AUROC values remained comparable using other definitions of clinically significant disease including UCL/Ahmed definition 2 (P = 0.79), Gleason ≥3 + 4 (P = 0.53) and Gleason ≥4 + 3 (P = 0.53).
CONCLUSIONS: Using 3T MRI, a high level of diagnostic accuracy can be achieved using T2W as a single parameter in men with a prior biopsy; however, such a strategy can lead to a higher rate of equivocal lesions.
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; biparametric MRI; diffusion-weighted imaging; dynamic contrast enhancement; prostate cancer; transperineal template prostate mapping biopsy

Mesh:

Substances:

Year:  2019        PMID: 31733173     DOI: 10.1111/bju.14953

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.969


  3 in total

1.  Diagnostic Ability of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer and Clinically Significant Prostate Cancer in Equivocal Lesions: A Systematic Review and Meta-Analysis.

Authors:  Jing Zeng; Qingqing Cheng; Dong Zhang; Meng Fan; Changzheng Shi; Liangping Luo
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

Review 2.  Current Status of Biparametric MRI in Prostate Cancer Diagnosis: Literature Analysis.

Authors:  Mason James Belue; Enis Cagatay Yilmaz; Asha Daryanani; Baris Turkbey
Journal:  Life (Basel)       Date:  2022-05-28

3.  Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density.

Authors:  Mads Ryø Jochumsen; Jens Sörensen; Bodil Ginnerup Pedersen; Jens Randel Nyengaard; Søren Rasmus Palmelund Krag; Jørgen Frøkiær; Michael Borre; Kirsten Bouchelouche; Lars Poulsen Tolbod
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-18       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.